Brought to you by:
SurVeil DCB demonstrates sustained durability of safety, efficacy endpoints in TRANSCEND
In the TRANSCEND clinical trial, the SurVeil drug-coated balloon (DCB; Surmodics) demonstrated “excellent efficacy and safety” out to 24-month follow-up. This is according to Kenneth Rosenfield, MD, from Massachusetts General Hospital in Boston, who presented the new data at Vascular…
IN.PACT Admiral DCB performs well across wide range of clinical, anatomical scenarios in pooled analysis
In a pooled analysis of the predictors of drug-coated balloon (DCB) effectiveness, the IN.PACT Admiral DCB (Medtronic) performed well across a broad range of clinical, anatomical and procedural scenarios. This is according to Prakash Krishnan, MD, an interventional cardiologist at Mount Sinai…
VIVA 2021: IN.PACT Admiral DCB found to provide ‘high five-year freedom from clinically driven TLR’ in patients with complex lesions
Real-world data drawn from the IN.PACT Global study looking at five-year freedom from clinically driven target lesion revascularization (TLR) among prespecified chronic total occlusion (CTO), long lesion and de novo in-stent restenosis (ISR) cohorts “continues to confirm long-term clinical safety…